A Novel De Novo Frameshift Variant of TBL1XR1 Leads to Neurodevelopmental Disorders and Treatment Experience
International Journal of Developmental Neuroscience · 2026-06 · 86 (4)
DOI: 10.1002/jdn.70148 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Developmental Neuroscience, online erschienen am 12.06.2026. Verfasst von Fangfang Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, China. Hauptthemen laut MEDLINE: Receptors, Cytoplasmic and Nuclear, Repressor Proteins, Neurodevelopmental Disorders, Frameshift Mutation. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Neurodevelopmental disorders were a wide range of cognitive and behavioural disorders. Its pathogenic genes, transduction beta like 1 X‐linked receptor 1 ( TBL1XR1 ), had been a hot research topic recently. However, reports involving treatment and long‐term follow‐up were still limited.
Methods
Exome sequencing of the family was performed. The clinical data and genetic variants, treatment and long‐term follow‐up were summarized. Moreover, treatment of published cases was also summarized to systematically understand its treatment strategies.
Results
Genetic screening revealed a de novo variant of TBL1XR1 [NM_024665.7: c.1372_1387dup, p.Asp463Glyfs*6]. The variant was a 16‐bp nucleotide duplication in exon 14, caused a conversion of the aspartic amino acids to glycine amino acids at the 463rd and finally generated a stop codon 6 amino acids after the 462nd amino acids. It was classified as a variant of pathogenic (P) according to the ACMG (American College of Medical Genetics and Genomics) guidelines. Valproic acid was administered up to 20 mg/kg/day, which resulted in satisfactory seizure control. Long‐term follow‐up confirmed the complete disappearance of seizures at 5 and 6 months of age, although hyperactivity, attention deficit and global developmental delay persisted.
Conclusion
Our results expanded the pathogenic variant spectrum and treatment of TBL1XR1 ‐related neurodevelopmental disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Jiangxi Provincial Children's Hospital, Nanchang, China.
ORCID-Profile: Jian Zha
Zitieren
APA
Cao, F., Xie, J., Huang, Z., Xiong, L., & Zha, J. (2026). A Novel De Novo Frameshift Variant of TBL1XR1 Leads to Neurodevelopmental Disorders and Treatment Experience. International Journal of Developmental Neuroscience, 86(4). https://doi.org/10.1002/jdn.70148
Vancouver
Cao F, Xie J, Huang Z, Xiong L, Zha J. A Novel De Novo Frameshift Variant of TBL1XR1 Leads to Neurodevelopmental Disorders and Treatment Experience. International Journal of Developmental Neuroscience. 2026;86(4). doi:10.1002/jdn.70148
BibTeX
@article{Cao2026,
author = {Cao, Fangfang and Xie, Jihua and Huang, Zhixin and Xiong, Ling and Zha, Jian},
title = {A Novel De Novo Frameshift Variant of TBL1XR1 Leads to Neurodevelopmental Disorders and Treatment Experience},
journal = {International Journal of Developmental Neuroscience},
year = {2026},
volume = {86},
number = {4},
doi = {10.1002/jdn.70148}
}
EUVIMED